Initiator Pharma (Sweden) Insiders
| INIT Stock | 3.04 0.05 1.67% |
Initiator Pharma employs about 3 people. The company is managed by 8 executives with a total tenure of roughly 7 years, averaging almost 0.0 years of service per executive, having 0.38 employees per reported executive. Reviewing how management performs at Initiator Pharma AS provides context around adaptability, decision quality, and the consistency of business execution. That matters because management quality often influences how well a company responds when business conditions become less favorable.
| Dan Peters Insider CoFounder CTO |
| Allan Wehnert Insider VP Management |
Initiator |
Management Team Effectiveness
The company has return on total asset (ROA) of -49.2 % which indicates that it has lost $49.2 on every $100 of assets. This falls well below what is typical for the industry. Similarly, it shows a return on equity (ROE) of -104.88 %, which implies that it generated negative returns to current shareholders.Outstanding Bonds
Outstanding bonds linked to Initiator Pharma AS can tell investors a great deal about how the company finances itself beyond common equity markets. Current market capitalization is about 319.34 Million. Bond investors and equity investors often care about the same cash flows, but they rank the risks differently.
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Holders Distribution
Institutional ownership analysis for Initiator Pharma AS matters because banks, hedge funds, pension plans, and other professional investors can influence price and liquidity more forcefully than smaller holders. Used correctly, the ownership map shows where professional sponsorship may be strong and where exit risk could still be significant.
Workforce Comparison
Initiator Pharma AS is rated below average in number of employees relative to competitors. The total workforce of Biotechnology industry is currently estimated at about 156. Initiator Pharma claims roughly 3.0 in number of employees contributing just under 2% to market share in Biotechnology space.
Benchmark Summation
Operator |
This analysis covers sixty-one data points across the selected time horizon. Initiator Pharma Price Series Summation is a cross summation of Initiator Pharma price series and its benchmark/peer.
Notable Stakeholders
Stakeholders matter for Initiator Pharma because not every influential participant is a shareholder acting with the same objective or time horizon. The practical value is that investors can see where interests align, where they conflict, and how that tension could influence execution.
| Dan Peters | CoFounder CTO | Profile | |
| Allan Wehnert | VP Management | Profile | |
| Susanne Thomsen | Head Ops | Profile | |
| Mikael MSc | CoFounder CDO | Profile | |
| Rene Egebro | Head CMC | Profile | |
| Claus Olesen | CEO CoFounder | Profile | |
| Torgeir Vaage | Chief Officer | Profile | |
| Pr Simonsen | CMO CoFounder | Profile |
Management Information & Data Sources
Initiator Pharma is a small-cap company. Executive review focuses on insiders, senior management, and employee signals. Management quality is often reflected indirectly through margin durability, reinvestment choices, and governance signals. CEO is Claus Olesen with 3 employees and 8 reported executives.
Unless otherwise specified, data for Initiator Pharma AS is compiled from periodic company reporting and market reference feeds and standardized for comparability. Updates may occur throughout the day. Insider and management fields are mapped from published filings and company disclosures.
This content is curated and reviewed by:
Raphi Shpitalnik - Junior Member of Macroaxis Editorial BoardWorkforce Efficiency and Productivity
Manpower analysis for Initiator Pharma AS matters because revenue per employee and profit per employee can reveal shifts in productivity and operating discipline. Used correctly, manpower metrics can highlight whether growth is being supported by better productivity or by heavier staffing costs.
Initiator Pharma Manpower Efficiency
Return on Initiator Pharma Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 7M | |
| Net Loss Per Executive | 2.6M |
Additional Tools for Initiator Stock Analysis
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments |